spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  gene editing 

 HSMN NewsFeed - 17 Apr 2024
Sensorium Therapeutics Appoints Sam Rasty as Chief Business Officer
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 25 Mar 2024
Poseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 1 Mar 2023
Chroma Medicine Secures $135M in Series B Financing to Advance Breakthrough Epigenetic Editing Technology and Expand Pipeline of Durable Precision Genomic Medicines
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 3 Feb 2023
Treadwell Therapeutics Announces the Appointment of Roger Sidhu, M.D., as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 16 Dec 2022
Curate Biosciences Announces David Backer as Chief Executive Officer
Regenerative Medicine Personnel
 HSMN NewsFeed - 3 Oct 2022
Alexion, AstraZeneca Rare Disease to Acquire LogicBio(R) Therapeutics to Accelerate Growth in Genomic Medicine
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 19 Aug 2022
Verismo Therapeutics Announces Submission of IND Application to the FDA for SynKIR-110TM, a KIR-CAR T-cell Immunotherapy Candidate
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 20 Dec 2021
Merck Acquires Chord Therapeutics to Expand Neuroinflammatory Pipeline
Biopharmaceuticals Neurology Mergers & Acquisitions
 HSMN NewsFeed - 24 Nov 2021
Next-generation Precision Medicine Company Allorion Therapeutics Completes Series A Financing Round
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 13 Oct 2021
Poseida Therapeutics Announces Leadership Appointments
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Sep 2021
Obsidian Therapeutics Announces Closing of $115 Million Series B Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 30 Aug 2021
Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-BCMA-ALLO1, an Allogeneic CAR-T Candidate for Relapsed/Refractory Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 13 Jul 2021
Prime Medicine Launches with $315 Million Financing to Deliver on the Promise of Prime Editing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 19 May 2021
LogicBio Therapeutics Promotes Daniel Gruskin, MD, to Chief Medical Officer and Announces Additional Leadership Appointments
Biopharmaceutical Personnel
 HSMN NewsFeed - 10 May 2021
LogicBio Therapeutics Strengthens Management Team with Key Appointments
Regenerative Medicine Personnel
 HSMN NewsFeed - 23 Mar 2021
Poseida Therapeutics Announces Carl June, M.D., to Chair Immuno-Oncology Scientific Advisory Board
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Mar 2021
Merck KGaA, Darmstadt, Germany, Reports Topline Data for Bintrafusp Alfa as Second-Line Monotherapy Treatment in Biliary Tract Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Mar 2021
Merck KGaA, Darmstadt, Germany, Builds on Leadership in Head and Neck Cancer Through Worldwide Licensing Agreement with Debiopharm for Pivotal-Stage Xevinapant
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 11 Dec 2020
BAVENCIO(R) (avelumab) Receives Positive CHMP Opinion for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 3 Dec 2020
Merck KGaA, Darmstadt, Germany and Artios Pharma Announce a Global Strategic Collaboration on Novel DNA Damage Response Targets in Oncology
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Oct 2020
Citius Pharmaceuticals Signs an Exclusive Worldwide Licensing Agreement with Novellus Therapeutics for Unique iMSC-Therapy for Acute Inflammatory Respiratory Conditions including COVID-19 Related Acute Respiratory Distress Syndrome (ARDS)
Biopharmaceuticals Regenerative Medicine Licensing
 HSMN NewsFeed - 25 Aug 2020
FDA Accepts Filing of New Drug Application for Tepotinib for the Treatment of Patients with Metastatic NSCLC with METex14 Skipping Alterations
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 Jul 2020
APEIRON Biologics and MaxCyte Enter into Clinical and Commercial Licensing Agreement for APN401
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 25 Jun 2020
Poseida Therapeutics Raises $110 Million in Series D Financing
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 7 May 2020
Caribou Biosciences and MaxCyte Enter into Clinical and Commercial License Agreement
Biopharmaceuticals Licensing
 HSMN NewsFeed - 9 Apr 2020
EMD Serono and Pfizer Receive US FDA Breakthrough Therapy Designation and Submit Application for BAVENCIO(R) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 24 Mar 2020
MaxCyte and Allogene Therapeutics Sign Clinical and Commercial License Agreement to Enable the Advancement of Allogeneic CAR T (AlloCAR T(TM)) Therapies
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 13 Mar 2020
EMD Serono and Pfizer Provide Update on Phase III JAVELIN Head and Neck 100 Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Sep 2019
Merck KGaA, Darmstadt, Germany, Announces FDA Breakthrough Therapy Designation for Investigational Therapy Tepotinib in Patients with Metastatic NSCLC with METex14 Skipping Alterations
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Jan 2019
Merck KGaA, Darmstadt, Germany, Grants Exclusive License to Vertex for Two DNA Damage Response Inhibitors
Biopharmaceuticals Licensing
 HSMN NewsFeed - 20 Dec 2018
Merck KGaA, Darmstadt, Germany, Assigns Chimeric Antigen Receptor T-cell (CAR-T) Rights to Intrexon
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 11 Dec 2018
GenEdit Closes $8.5 million Series Seed Financing
Regenerative Medicine Venture Capital Personnel
 HSMN NewsFeed - 10 Dec 2018
Merck KGaA, Darmstadt, Germany Announces FDA Orphan Drug Designation for Bifunctional Immunotherapy M7824 in Biliary Tract Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 19 Nov 2018
Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Avelumab in Platinum-Resistant/Refractory Ovarian Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Nov 2018
Precision BioSciences and MaxCyte Enter into Clinical and Commercial License Agreement
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 30 Aug 2018
RootPath Raises $7 Million Seed Round led by Sequoia China to Accelerate Its Cancer Immunotherapy Programs
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 6 Aug 2018
CureGenetics raises $17 million in Series A Financing
Biopharmaceuticals Diagnostics Personnel
 HSMN NewsFeed - 23 Jul 2018
Sangamo Therapeutics to Acquire TxCell
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 13 Jun 2018
StrideBio Closes $15.7 Million Series A Financing to Advance Transformational AAV Platform
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 2 May 2018
Refuge Biotechnologies Completes $25 Million Series B Financing, Appoints CSO to Advance the Development of Intelligent Cell Therapies in Oncology
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 25 Apr 2018
MaxCyte Appoints Dr. Claudio Dansky Ullmann as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Apr 2018
Dr. Ottavio Vitolo Joins Relmada Therapeutics as Senior Vice President, Head of R&D and Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Apr 2018
Abeona Therapeutics Appoints Carsten Thiel, Ph.D., as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Feb 2018
Poseida Therapeutics Appoints Mark Gergen as Chief Business Officer and Chief Financial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 22 Feb 2018
Kite, a Gilead Company, And Sangamo Therapeutics Announce Collaboration To Develop Next-Generation Engineered Cell Therapies For The Treatment Of Cancer
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 14 Aug 2017
MaxCyte Appoints Executive Vice President of Global Marketing
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 31 May 2017
Homology Medicines Strengthens Manufacturing and Product Development Expertise with Appointment of Tim Kelly as Senior Vice President, Technical Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Mar 2017
eGenesis Announces $38 Million Series A Financing, Led by Biomatics Capital and ARCH Venture Partners, to Solve Shortage of Organs for Donation
Regenerative Medicine Venture Capital
 HSMN NewsFeed - 12 Dec 2016
Bayer and Versant Ventures Join Forces to Launch Stem Cell Therapy Company BlueRock Therapeutics with USD 225 Million Series A Financing
Regenerative Medicine Venture Capital
 HSMN NewsFeed - 12 Oct 2016
RXi Pharmaceuticals Enters into Exclusive Option Agreement to Acquire MirImmune Inc.
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 19 Aug 2016
Bayer and CRISPR Therapeutics joint venture, named Casebia Therapeutics, establishes operations in Cambridge, MA
Biopharmaceuticals
 HSMN NewsFeed - 6 Jun 2016
Homology Medicines Appoints James Warren, Ph.D. as Vice President of Manufacturing
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 May 2016
Caribou Biosciences Raises $30 Million in Series B Funding
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 13 May 2016
WaferGen Bio-systems and Takara Bio Inc. Announce Merger Agreement
Diagnostics Mergers & Acquisitions
 HSMN NewsFeed - 1 Sep 2015
Intellia Therapeutics Secures $70 Million in Series B Financing
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 14 Jul 2015
Transgenomic Launches Most Comprehensive Genetic Test for Diagnosis of Leukodystrophy
Diagnostics Product Launch
 HSMN NewsFeed - 18 Nov 2014
Intellia Therapeutics Announces $15 Million in Funding to Develop Therapeutic Products Utilizing CRISPR-Cas9 Gene Editing Technology
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 24 Jun 2014
Editas Medicine Appoints Katrine S. Bosley to Chief Executive Officer
Biopharmaceuticals Personnel
Return to NewsFeed  

 Additional items found! 4

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 4 additional stories matching:
gene editing
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.